Subscribers

Brokers’ take: Maybank flags potential jackpot for Genting from its pharma unit’s Alzheimer’s drug

MAYBANK has marked Genting Bhd for a potential spike in value after its 20 per cent-owned pharmaceutical unit TauRx announced positive results for its lead investigative drug in the third phase of its Alzheimer's disease (AD) study.

The research house has reiterated its "buy" rating and target price of RM5.25 for the counter pending an analyst briefing. Analyst Yin Shao Yang notes that "if TauRx is worth US$15 billion, Genting could well be worth a much higher RM8.57 per share".

The study by TauRx...

KEYWORDS IN THIS ARTICLE

READ MORE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes